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Abstract
Background: To investigate the effect of supplementation of standard treatment (inhaled long-acting β2 agonists,
anticholinergics and corticosteroids) with vitamin D on C reactive protein and pulmonary function tests in patients
with COPD exacerbation.
Methods: Design: Randomized, single-center, double-blind, placebo-controlled parallel trial. One teaching hospital
Participants: 135 patients in pulmonary ward with moderate to severe COPD and exacerbations.120 patients fulfilled
the study protocol. Interventions: Patients were randomly divided into three groups receiving 7 day treatment with
0.25 μg calcitriol daily (n = 45), 50000 IU daily of vitamin D (n = 45) or placebo (n = 45). An independent nurse was
responsible for allocation, preparation, and accounting of trial medications. Main Outcome measures: Maximal
expiratory flow volume (FEV1) and forced volume capacity curves (FVC) and Modified Medical Research Council
(MMRC) scale.
Results: Out of 135 patients who were recruited consecutively, 45 patients randomly were randomly assigned in three
groups (balance blocked randomization.15 patients were dropped out due to non-compliance for second PFT. Intention
to treat analysis was carried out for 120 participants. The difference between before and after treatment FEV1 and FEV1/
FVC ratio had no significant difference between treatment groups and placebo. (P = 0.43, P = 0.51, respectively)but clinical
improvement was significant in patients who received calcitriol. No side effects were reported.
Conclusions: Short term treatment with either calcitriol or 25(OH) 2Vit D didn’t changed FEV1 or FVC in vitamin D
sufficient patients with COPD exacerbation; nevertheless it can provide clinical benefit.
Trial registration: Trial registration: Iranian Registry of Clinical Trials no. IRCT138712271774N1. Registered 10 April 2011.
Keywords: Calcitriol, COPD, Forced expiratory volume, Forced Vital Capacity, Pulmonary function tests, Vitamin D
Abbreviations: Alb, Albumin; Ca, Calcium; 25OH-D, Vitamin D; 1,25OH-D, 1,25Vitamin D; CRP, C reactive protein;
Calcitriol, Calcitriol
Background
Chronic obstructive pulmonary disease (COPD) is the
fourth main cause of death in the United States [1].
Many studies have shown 25-OHD serum levels in pa-
tients suffering from COPD.
Vitamin D deficiency in African-Americans is closely as-
sociated with higher susceptibility to COPD [2, 3]. Also,
the studies suggest that there is a link between genetic
variants in the vitamin D pathway and COPD. For ex-
ample, studies suggest that a single nucleotide polymorph-
ism (SNP) of the vitamin D binding protein protects
COPD through a mechanism that is still unknown to re-
searches [4].
The VDR levels is significantly low in lung tissues
of COPD patients [5]. Active metabolite of vitamin D
(1, 25 dihydroxy vitamin D3) has a vital role in cellu-
lar metabolism and differentiation by means of its nu-
clear receptor (VDR) that is associated with a number
of other chromatin modification enzymes (histone
acetyltrans-ferases and histone deacetylases), and
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therefore involved in the complex epigenetic events in
vitamin D signaling and metabolism [6].
Recently, studies have found a linear correlation be-
tween higher risks of vitamin D deficiency in patients
with COPD and the function of lung and systemic levels
of vitamin [7, 8]. Nevertheless in a cohort study carried
out on patients with severe COPD, baseline 25 (OH) D
levels could not predict the ensuing acute exacerbation
of COPD [8]. Patients with COPD are subjected to
exacerbation. The symptoms of exacerbations are nor-
mally severe deterioration of symptoms, intense airway
inflammation and physiological worsening [9]. They are
assumed to act as a reference in the therapeutic study of
COPD. Recently, some studies have found the effect of
exacerbations on disease progression, which can be
manifested by accelerated forced expiratory volume in
one second (FEV1), and reduced characteristic of COPD
[10, 11]. Brehm showed that vitamin D deficiency is
related to severe of allergy and asthma attacks. There
was a significant and inverse relationship between the
level of Serum vitamin D and increased airway respon-
siveness [12]. Exacerbations is estimated to be the cause
of nearly 25 % of the FEV1 decline in COPD [10].
With the exception of smoking quitting, no other
proved treatment has been found for hindering COPD
disease progression; however, two recent large random-
ized controlled experiments have shown the positive im-
pacts of long-acting bronchodilators on the rate of
exacerbation, life quality, and survival [11, 13].
It is while the inefficacy of a host of new therapeutics
or recombinant antibodies have been proved. In light of
the unsatisfactory results of these expensive medications,
greater attention should be paid to the potential of trad-
itional medications. The potential therapeutic effect of
drugs such as statins, angiotensin-converting enzyme
(ACE)–inhibitors, and heparin have not been recognized
and they may attract greater attention in future therapy
of COPD [14, 15]. This study explores the potentials of
another, even older molecule, vitamin D.
A cross-sectional, retrospective study of children
there is a relationship between in Costa Rica show that
vitamin D deficiency and higher symptoms of asthma
severity [12]. Another study suggested the higher risk
of severe asthma exacerbation in patients suffering
from vitamin D insufficiency [16]. The aim of this
study is to evaluate the role of exogenous addition of
vitamin D and 1, 25 dihydroxy vitamin D on the func-
tion of lung in the patients suffering from COPD
exacerbation.
Methods
Study Design and Participants: The current study was a
single-center, double-blind research, which used parallel
group and randomized placebo-controlled trial. Two
hundred and five patient were assessed for eligibility
(Not meeting inclusion criteria, n = 38 & Declined to
participate, n = 32). A total of 135 patients aged between
40 and 60 years were recruited consecutively diagnosed
as having COPD from the emergency department of
Kerman Afzalipour university Hospital in Kerman city
(the largest province in south east of Iran) during winter
of 2011. All subjects were ex-smokers with a history of
chronic cough and expectoration who also had exer-
tional dyspnea and were admitted with the diagnosis of
COPD exacerbation.
Based on the ERS criteria, COPD defined when FEV1 %
prediction is <88 % for men, or <89 % for women [17, 18].
An acute exacerbation of COPD can be defined as a dra-
matic degradation of COPD symptoms (for example, the
quantity and the color of phlegm or shortness of breath)
that last for a couple of days [19].
Patients were excluded if the following were presented:
unwillingness to participate in the study, unable to per-
form spirometry, A history of asthma symptoms, exist-
ence of other respiratory disorders including bronchial
carcinoma, a history of hospitalization (within 4 weeks)
for COPD, any medical condition which needed more
invasive respiratory support, symptoms of lower respira-
tory tract infection or other kinds of simultaneous
systemic disease such as hypercalcemia, renal failure,
hyperparathyroidism, malignancy, history of renal stone,
cardiac arrhythmia, or patients who were using lithium.
All subjects signed an informed written consent to
participate in the study. The protocols of the study were
confirmed by the ethics committee of KUMS [Kerman
university of medical sciences (Code 88/17)], and this
trial was registered on the IRCT [Iranian Registry of
Clinical Trials] website (the registration number of the
trial is IRCT138712271774N1). We tried this random-
ized controlled trials conform to the CONSORT state-
ment and flow diagram (Fig. 1) [19].
Full trial protocol can be accessed in Iranian Registry
of Clinical Trials website.
Randomization and Masking: In this study, we used a
double-blind randomized, parallel group, placebo-
controlled design. After the preliminary evaluation, the
qualified patients were randomly assigned to one of the
three treatment groups and followed up for one week.
Participants were randomized by a computer-generated
list to 3 equal groups. Patients were divided into 3
groups according to the balance blocked randomization.
Out of 135 patients, 45 patients randomly were selected
in three groups of A, B and C. Patients in each group
received same envelopes containing different drugs. Both
patients and the physicians and epidemiologist were
blinded to the treatment received. A nurse who was not
involved in care of the trial patients and independent of
the site investigator was responsible for allocation,
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preparation, and accounting of trial medications. The
trial medications and placebo was prepared at a separate
site, and then taken to the clinic every week. The
randomization schedule was thus concealed from all
care providers, ward physicians, and other research
personnel. The patients who left the study or for whom
the experiment could not be completed were excluded,
and finally3, 6 and 6 patients were eliminated in groups
A, B and C respectively. No side effect or harm was
reported.
In phone recall all of eliminated patients were alive
and improved clinically after one week but they didn’t
participate to the last part of the study (Second PFT and
Lab Tests) due to personal problems.
Procedures
After randomizing the patients, there were follow-up
visits at the beginning and the end of study (day 0 and
8). Patient received the following treatment. Group A:
Placebo (n = 42) - The patients in this group received
standard treatment for COPD according to the guide-
lines of GOLD [20].
Also, these patients received placebo capsules, which were
similar to active drug in group B and C, daily for a week.
Group B: Treatment with vitamin D supplementa-
tion (N = 39. Similar to in group A, these patients
received standard treatment for COPD in addition
to25 (OH)-D3 (Pourateb, Iran) 50000 IU capsules
Daily for seven days. Group C: Treatment supple-
mented with calcitriol (n = 39).
Standard COPD treatment was given to these pa-
tients according to the guidelines of GOLD [20, 21]
plus calcitriol (Pourateb, Iran) 0.25 μg capsules daily,
for seven days.
If necessary, inhaled salbutamol was permitted. Also,
to control exacerbations, additional bronchodilators, oral
steroids and antibiotics were used.
Corticosteroid therapy (oral or inhaled), if present, could
continue without any change. Spirometry: Spirometry was
Patients were assessed for 
eligibility (n=205)
Excluded  =(n=70)
 ♦ Not meeting inclusion criteria 
(n=38) 
♦ Declined to participate (n=32)
♦ Other reasons (n=0) 
Randomly assigned
(n=135)
Were assigned to receive 
VitD (n=45)
Were assigned to receive 
Calcitrol (n=45)



























Completed the study 
(n=39)
Excluded (n=0)
Analysis Intention to treat 
Allocation Allocation 
Follow-Up
Analysis Intention to treat 
Fig. 1 Study flow diagram
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carried out at the beginning and the end of study (day
0 and 8).
The experiment was carried out on a dry, rolling-seal
spirometer Benchmark model (Spirolab, UK).
According to the guidelines of American Thoracic
Society/European Respiratory Society Maximal expira-
tory flow volume and forced volume capacity curves
were attained. For each subject, three acceptable and a
minimum of two reproducible curves were obtained.
The greatest values of FEV1 and FVC were chosen
for analysis. we used the Modified Medical Research
Council (MMRC) scale for the evaluation of dyspnea
in everyday activities at day 0 and 8 in each group
[22] [Table 1].
Biochemical estimations: All serum samples were
stored frozen at −80 C. Serum calcium was measured
for excluding hypercalcemic patients and albumin was
checked for interpreting the calcium results. C-reactive
protein (CRP) was measured when the follow-up period
was terminated. High sensitivity CRP concentrations
were measured on a Hitachi 911 analyzer by a latex-
enhanced immuneturbidimetric assay from Roche.
Circulating25 (OH) D3, and1, 25(OH) 2VITD was mea-
sured by Stat Fax Instrument and Immunodiagnostic
System Kit using an Enzyme immunoassay method.
In each set of samples, we measured two internal con-
trol specimens that the reagent manufacturer had pro-
vided. The total variation coefficient of for measured
internal controls was 9.3.
In the final stage of treatment, responses were assessed
by a physician, who asked patients about the improve-
ment, stability or deterioration of their condition.
The primary end points were FEV1 and FVC and
clinical response. Secondary end points were serum
level of C reactive protein, totalanti-oxidant, 25 and
1&25OH- vitamin D.
Statistical Analysis: For convenience, STATA statistical
software was used for determining the sample size.
SPSS 16 (Chicago, IL) was used for statistical analysis.
Paired t test and Mann Whitney test were respectively
used for data with and without normal distribution. To
compare categorical variables within three groups, Chi
square test (and Fisher exact test if required) was used.
Similarly the changes in the outcome parameters were
compared by univariate analysis of variance (ANOVA)
and followed by Bonferroni correction. To control the
effects of first value FEV1 and FEV1/FVC, two-way
ANOVA (ANCOVA) was used. All collected data were
included in the intention to treat analysis.
The statistical significance level was considered less
than 0.05 (P value < 0.05).
Results
One hundred and twenty patients who had COPD
exacerbation met the eligibility criteria and completed
the trial. The details of the population are summarized
in [Table 2]. Statistically, treatment arms were not
Table 1 The modified Medical Research Council dyspnea scale
(MMRC)
Grade of dyspnea Symptom
Grade 0 Not troubled by breathlessness except on strenuous exercise
Grade 1 Short of breath when hurrying or walking up a slight hill
Grade 2 Walks slower than contemporaries on the level because of
breathlessness or has to stop for breath when walking at own
pace
Grade 3 Stops for breath after walking 100 m or after a few minutes on
the level
Grade 4 Too breathless to leave the house or breathless when dressing
or undressing









58.4 ± 9.5 55.8 ± 9.5 55.6 ± 10.4 0.382
Sex, %
Male 69.2 71.4 87.2 0.128
Female 30.8 28.6 12.8
FEV1
Baseline 46.7 ± 20.4 45.3 ± 18.9 46.3 ± 17.5 0.439
End 62.3 ± 22.9 64.5 ± 22.8 64.1 ± 21.3
FEV1/FVC
Baseline 70.2 ± 16.9 68.2 ± 16.9 69.1 ± 17.2 0.513
End 72.9 ± 14.1 73.1 ± 14.2 74.4 ± 15.4
MMRC
3.62 ± 0.49 3.69 ± 0.46 3.6 ± 0.49* 0.001
2.66 ± 0.74 2.65 ± 0.67 1.98 ± 0.65
Data are expressed as mean ± SD
*different from placebo p ≤ 0.05
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significantly different with respect to age and gender and
severity of disease which is shown pre-treatment FEV1
and FEV1/FVC ratio. There was not a significant statis-
tical difference between Calcium and Albumin and C
reactive protein (P value > 0.05). At the end of study,
none of the patient developed hypercalcemia [Table 3].
The baseline-anticipatedFEV1 percent was the same in
the three groups (Table 2). The FEV1 percent predicted
in Calcitroil group showed an increase from 46.3 ± 17.5
at baseline to 64.1 ± 21.3 after treatment (P < 0.01). In
Vitamin D group, it rose from 45. 3 ± 18.9 to 64.5 ± 22.8
after treatment (P < 0.01), and in Placebo group, 46.7 ±
20.4 reached to 62.3 ± 22.9 (P < 0.01). The difference be-
tween before and after treatment FEV1 and FEV1/FVC
ratio was calculated and compared between groups by
ANOVA and it no significant difference was observed
between treatment groups and placebo.(P = 0.43, P =
0.51, respectively) After adjusting the effect of baseline
FEV1 and FEV1/FVC ratio by ANCOVA the result
didn’t changed too (P = 0.44, P = 0.54, respectively). The
magnitude of increase in FEV1 and FEV1/FVC ratio was
corresponding in the three groups. However, clinically
improved lung function(Reduction in MMRC) was ob-
served in all cases and was significant in the majority of
patients. The MMRC in Calcitroil group showed a sig-
nificant decrease from 3.6 ± 0.49 at baseline to 1.98 ±
0.65after treatment (P < 0.0001). In Vitamin D group, it
decreased from 3.69 ± 0,46 to 2.65 ± 0.67 after treatment
(P < 0.001), and in Placebo group, 3.62 ± 0.49reached to
2.62 ± 0.74 (P < 0.01). The difference between before and
after treatment MMRC was calculated and compared
between groups by ANOVA and Tukey test and signifi-
cant difference was observed between calcitriol group vs.
placebo (1.46 vs. 0.71 P < 0.001). Maximum reduction in
MMRC was seen in calcitriol group and then vitamin D
and placebo group respectively (P < 0.001).
Statistically speaking, there was no relationship be-
tween FEV1 and changed FEV1with serum level of 25
OH-vitamin D and 1,25 (OH)2 vitamin D before and after
treatment (P > 0.1) there was a significant rise in the
levels of plasma vitamin 25OH-D in Vitamin D group
from58.9 ± 27 nmol/l at baseline to 97.7 ± 52.2 nmol/l
after treatment (P < 0.001). In Calcitriol group, however,
the variation from 54.9 ± 34.9 to 57.1 ± 44.4 nmol/l was
not significant. The same result was seen in placebo
group. The plasma level of 1,25OH-D was not affected
significantly by any of treatments [Table 3].
Discussion
This study revealed that short term treatment with nei-
ther calcitriol nor vitamin D has any effect on pulmon-
ary function of COPD patients during exacerbation,
nevertheless the MMRC in Calcitroil group showed a
significant decrease. The level of calcitriol did not
change during this study, but the increase in 25(OH)
vitamin D in group B indicated the compliance of the
patient in ingesting the drug.
A number of studies have stated 25-OHD serum levels
in COPD patients. One recently published study showed
that aspiratory muscle strength and maximal oxygen
Table 3 Effect of treatments on Calcium, Albumin,CRP and different forms of vitamin D
Variables Placebo (n = 42) Vitamin D (n = 39) Calcitriol (n = 39) P. Value
Albumin (g/l)
Baseline 39.05 ± 4.37 38.71 ± 5.7 39.7 ± 4.9 0.66
Post-Baseline(End) 43.2 ± 4.1 42.1 ± 4.2 43.4 ± 5.1 0.33
Difference (change) 4.2 ± 3.9 3.4 ± 3.7 3.76 ± 4.8 0.67
Calcium (mmol/l)
Baseline 2.4 ± 0.19 2.46 ± 0.13 2.43 ± 0.18 0.43
Post-Baseline(End) 2.6 ± 0.15 2.6 ± 0.12 2.6 ± 0.12 0.076
Difference (change) 0.19 ± 0.18 0.20 ± 0.16 0.17 ± 0.14 0.78
CRPa (Mg/dL)
Baseline 70.1 ± 61.5 70.9 ± 52.1 67.3 ± 57.1 0.95
25OH-D(nmol/l)
Baseline 59.9 ± 26 58.9 ± 27 54.9 ± 34.9 <0.001
End 65.2 ± 39.2 97.7 ± 52.2* 57.1 ± 44.4
1,25OH-D(pmol/l)
Baseline 91. ±13.5 110.2 ± 71.2 103.5 ± 83.7 0.563
End 108.7 ± 59.5 128.2 ± 121.9 101.9 ± 81.1
aCRP:Creactive protein
*P < 0.001
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uptake in patients receiving vitamin D improved signifi-
cantly compared with placebo group, but two groups were
not statistically different in terms of improved quadriceps
strength or six minutes walking distance [23].
Also, high doses of vitamin D(100 000 IU every
4 weeks for 1 year) in vitamin D sufficient patients did
not have a significant effect on mean time before the
appearance of the first exacerbation, exacerbation
rates, FEV1, hospitalization, life quality, and death. In
participants who had acute vitamin D deficiency at
baseline, the use of supplementation could reduce ex-
acerbations [21].
The studies of Forli and colleagues showed that more
than 50 % of patients enlisted for lung transplantation
had vitamin D deficiency (<20 ng/ml) [24]. Likewise, a
study on community-dwelling patients in Denmark who
suffered from COPD revealed 68 % of the participants
had untreated osteoporosis or osteopenia [25]. It is
worth noting that insufficient or low levels of vitamin D
are not particular to COPD. Patients with COPD are
more likely to have vitamin D deficiency for several rea-
sons [3]. Vitamin D deficiency is a common problem in
most population yet [26, 27].
The current supplementation with a daily dose of 800
to 1,000 IU of vitamin D makes up for low levels of
serum 25-OHD in the majority of adults in concentra-
tions greater than 20 ng/ml, but higher doses may be
needed to increase 25-OHD levels proportional to the
needs of high-risk patients who don’t have hypocalcae-
mia [28]. One recent study suggest that “the current
vitamin D recommended dietary allowance (RDA)
(600 IU/day) is insufficient to cover the skeletal health
needs of at least 50 % of black and white children” [29].
In this study most patients were vitamin D sufficient
maybe due to extra use of vitamin D supplementation in
old population in our country [30]. It was shown that “
Vitamin D intake decreased COPD exacerbation and
improved FEV1 in the patients with severe and very se-
vere COPD” [31]. Unfortunately in this study which was
carried out in our country the baseline level of vitamin
D was not determined. It was shown that “vitamin D3
was protective against moderate or severe exacerbation
in participants with baseline serum 25-hydroxyvitamin
D concentrations of less than 50 nmol/L” too [32].
Our study showed no significant relationship between
vitamin D level and FEV1 and or FEV1/FVC, it may be
due to sufficient leveled vitamin D in the population of
our study. Unfortunately there were not enough vitamin
D deficient patients to do any statistical analysis in this
subgroup. The present study showed that any relation-
ship between vitamin D level and FEV1 or airway
responsiveness may be due to high levels of vitamin D in
the patients. The more important cause can be explained
by the difference between the pathophysiology of asthma
and chronic obstructive lung diseases a non-reversible
airway disease. The level of CRP didn`t significant differ-
ence between three groups it may emphasis that this
dose and duration of vitamin D and calcitriol can`t be
effective on reducing the inflammation. Due to the great
possibility of genetic involvement in Vitamin D's effect
on respiratory disease and the high prevalence of
Vitamin D deficiency in Iran, it is suggested to conduct
clinical trials among the Iranian people and evaluate the
efficacy of Vitamin D [33].
Our study had some limitations. First most of our pa-
tients were Vitamin D sufficient so we couldn’t deter-
mine the effect of short term treatment in patient
Vitamin D deficiency (which may be more effective).
Longer duration with larger sample size study in vitamin
D deficient patients with COPD suggests. Second our
study was too short to follow the patient for readmission
so we recommend study the effect of calcitriol on the
frequency of hospitalization. Third as this study were
done in normocalcemic patient we had chosen the low-
est dosage of calcitriol, higher doses of calcitriol can be
used in future studies.
Given the inefficacy of current treatments in COPD,
there is still a need for further randomized control trials
with vitamin D supplementation. In such randomized
controlled trials in which vitamin D treatment is only
based on bone maintenance, defining the optimal serum
levels for 25-OHD in this disease as reference for other
calcemic endpoints is a challenging task. Future clinical
trials are suggested to evaluate the impact of higher
levels of vitamin D and especially calcitriol on lung func-
tion during exacerbation. We suggest investigating this
correlation in vitamin D deficient patients.
Conclusion
Short term treatment with either calcitriol or 25(OH) 2Vit
D didn`t changed FEV1 or FVC in vitamin D sufficient
patients with COPD exacerbation; nevertheless it can pro-
vide clinical benefit.
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